false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Mesoscale Nanoparticles
Mesoscale Nanoparticles
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Ryan Williams presented polymeric mesoscale nanoparticles (MNPs) developed to deliver therapeutics to the kidneys. The 300–500 nm PLGA–PEG particles require no targeting ligand and, unlike many nanoparticles that accumulate in the liver, preferentially reach kidney tubules—especially proximal tubular epithelial cells—likely through uptake from peritubular capillaries. The biodegradable particles have shown good tolerability in rodents.<br /><br />Across collaborative studies, MNPs have delivered small molecules, peptides, siRNA, and mRNA in models of acute and chronic kidney injury, diabetic disease, polycystic kidney disease, and renal vascular disease. Examples included reducing cisplatin-induced kidney damage, lowering blood pressure through IL-1β siRNA delivery, and improving kidney perfusion after delivery of TSG6 mRNA. The group has also reported therapeutic effects in larger-animal studies and is exploring clinical translation.<br /><br />In discussion, Williams noted that the mechanisms determining cell-type uptake, movement into tubular cells, and greater accumulation in stenotic kidneys remain unclear. The team has evidence for active, dynamin-dependent uptake, but has not identified the relevant receptor or established whether rare kidney cell types are targeted. Future work will investigate delivery beyond proximal tubules, including to collecting ducts and podocytes, and refine cargo-release behavior.
Asset Caption
Ryan Williams, PhD
Meta Tag
Speaker
Ryan Williams
Keywords
polymeric mesoscale nanoparticles
kidney drug delivery
PLGA-PEG particles
proximal tubular epithelial cells
siRNA and mRNA therapeutics
acute and chronic kidney disease
renal targeted nanomedicine
Ryan Williams
×
Please select your language
1
English